The abstract is read at the publisher; the summary is JClub's.
FDA clearance has expanded for multiple brain stimulation modalities in neuropsychiatry, reflecting marked progress in both basic and clinical neuromodulation evidence.
- Why it matters: The field needs a clear view of which stimulation approaches work, what limits their therapeutic use, and where new breakthroughs could improve neuropsychiatric treatment.
- What they did: This review covers invasive and noninvasive electrical, magnetic, sonic, and related energy methods, including focal intracerebral drug delivery, targeted deep/superficial stimulation, resilience-focused interventions, and responsive closed-loop systems using personalized biomarkers.
- The result: It highlights emerging clinical utility, including noninvasive home-use stimulation with FDA clearance, and frames brain stimulation as a paradigm shift for neuropsychiatric therapeutics and mechanism discovery.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.